Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

@article{BassetSguin2017VismodegibIP,
  title={Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.},
  author={Nicole Basset-S{\'e}guin and Alexander Hauschild and Rainer Kunstfeld and Jean Jacques Grob and Brigitte Dr{\'e}no and Laurent Mortier and Paolo Antonio Ascierto and Lisa Licitra and Caroline Dutriaux and Lawrence G. Thomas and N Meyer and Bernard Guillot and Reinhard Dummer and Peter Arenberger and Kate M. Fife and Ana Rita Marcos Raimundo and Emi Dika and Natalie Dimier and Alberto Fittipaldo and Ioannis Xynos and Johan Hansson},
  journal={European journal of cancer},
  year={2017},
  volume={86},
  pages={
          334-348
        }
}
BACKGROUND The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed safety and efficacy of vismodegib-a first-in-class Hedgehog pathway inhibitor demonstrating clinical benefit in advanced basal cell carcinoma (BCC)-in a patient population representative of clinical practice. Primary analysis data are presented. PATIENTS AND METHODS Patients with locally advanced or metastatic BCC received oral vismodegib 150 mg/d until progressive disease, unacceptable… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Similar Papers

Loading similar papers…